Austar Lifesciences Ltd. (HK:6118) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Austar Lifesciences Ltd. has completed the acquisition of a 51% equity interest in a target company for $1.515 million, making it a wholly-owned subsidiary. This strategic move is aimed at enhancing market competitiveness and operational efficiency, as well as reducing costs by integrating resources within the group. The acquisition is expected to bolster Austar’s financial performance by leveraging the existing partnership with STERIS.
For further insights into HK:6118 stock, check out TipRanks’ Stock Analysis page.